Table 5.

Reporting odds ratio of ICSRs with nervous system disorders for the comparison of PCSK9Is versus statins

PCSK9i	Statin	ROR (95% CI)	p value
Evolocumab	Atorvastatin	1.55 (1.44–1.68)	< 0.001
Evolocumab	Simvastatin	1.12 (1.02–1.22)	0.013
Evolocumab	Pravastatin	1.11 (0.98–1.26)	0.098
Evolocumab	Rosuvastatin	1.00 (0.92–1.09)	0.976
Evolocumab	Fluvastatin	1.49 (1.25–1.77)	< 0.001
Alirocumab	Atorvastatin	1.58 (1.45–1.74)	< 0.001
Alirocumab	Simvastatin	1.14 (1.03–1.26)	0.011
Alirocumab	Pravastatin	1.13 (0.99–1.29)	0.067
Alirocumab	Rosuvastatin	1.02 (0.92–1.13)	0.676
Alirocumab	Fluvastatin	1.51 (1.27–1.82)	< 0.001

ICSR Individual Case Safety Reports, PCSK9Is proprotein convertase subtilisin/kexin type 9 inhibitors, ROR reporting odds ratio, CI confidence interval